The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies

Ronnie Shapira-Frommer,Jiaxin Niu,Ruth Perets,Solange Peters,Geoffrey Shouse,Iwona Lugowska,Marina C Garassino,Jacob Sands,Tanya Keenan,Bin Zhao,Jane Healy,Myung-Ju Ahn
DOI: https://doi.org/10.1080/14796694.2024.2343272
Abstract:Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT. The addition of vibostolimab to the PD-1 inhibitor pembrolizumab has shown promising antitumor activity, warranting further exploration of vibostolimab as a potential therapeutic option. The KEYVIBE program consists of nine trials that will evaluate the safety and efficacy of vibostolimab monotherapy and vibostolimab-based combination therapy in advanced solid tumors and hematological malignancies. These studies will also evaluate coformulated immunotherapy addressing issues that occur with the sequential administration of immunotherapy. The KEYVIBE program will provide further insight into the clinical utility of vibostolimab-based therapy across multiple indications and various stages of disease.
What problem does this paper attempt to address?